These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26895718)

  • 1. Aging and multiple sclerosis.
    Sanai SA; Saini V; Benedict RH; Zivadinov R; Teter BE; Ramanathan M; Weinstock-Guttman B
    Mult Scler; 2016 May; 22(6):717-25. PubMed ID: 26895718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and treatment of multiple sclerosis in elderly populations.
    Vaughn CB; Jakimovski D; Kavak KS; Ramanathan M; Benedict RHB; Zivadinov R; Weinstock-Guttman B
    Nat Rev Neurol; 2019 Jun; 15(6):329-342. PubMed ID: 31000816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MS progression is predominantly driven by age-related mechanisms - NO.
    McGinley M; Ontaneda D
    Mult Scler; 2019 Jun; 25(7):904-906. PubMed ID: 30747571
    [No Abstract]   [Full Text] [Related]  

  • 4. MS progression is predominantly driven by age-related mechanisms - YES.
    Scalfari A
    Mult Scler; 2019 Jun; 25(7):902-904. PubMed ID: 30747579
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.
    Frohman EM; Filippi M; Stuve O; Waxman SG; Corboy J; Phillips JT; Lucchinetti C; Wilken J; Karandikar N; Hemmer B; Monson N; De Keyser J; Hartung H; Steinman L; Oksenberg JR; Cree BA; Hauser S; Racke MK
    Arch Neurol; 2005 Sep; 62(9):1345-56. PubMed ID: 16157741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis and aging.
    Louapre C; Papeix C; Lubetzki C; Maillart E
    Geriatr Psychol Neuropsychiatr Vieil; 2017 Dec; 15(4):402-408. PubMed ID: 29081400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis in the elderly patient.
    Awad A; Stüve O
    Drugs Aging; 2010 Apr; 27(4):283-94. PubMed ID: 20359260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular comorbidities in the onset and progression of multiple sclerosis.
    Tettey P; Simpson S; Taylor BV; van der Mei IA
    J Neurol Sci; 2014 Dec; 347(1-2):23-33. PubMed ID: 25454639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
    Orthmann-Murphy JL; Calabresi PA
    Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking ageing into account in remyelination-based therapies for multiple sclerosis.
    Rist JM; Franklin RJ
    J Neurol Sci; 2008 Nov; 274(1-2):64-7. PubMed ID: 18539300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disturbed regulatory T cell homeostasis in multiple sclerosis.
    Venken K; Hellings N; Liblau R; Stinissen P
    Trends Mol Med; 2010 Feb; 16(2):58-68. PubMed ID: 20159585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression in multiple sclerosis: further evidence of an age dependent process.
    Koch M; Mostert J; Heersema D; De Keyser J
    J Neurol Sci; 2007 Apr; 255(1-2):35-41. PubMed ID: 17331540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remyelination capacity of the MS brain decreases with disease chronicity.
    Goldschmidt T; Antel J; König FB; Brück W; Kuhlmann T
    Neurology; 2009 Jun; 72(22):1914-21. PubMed ID: 19487649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral Inflammation and Demyelinating Diseases.
    Murta V; Ferrari C
    Adv Exp Med Biol; 2016; 949():263-285. PubMed ID: 27714694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.
    Frischer JM; Weigand SD; Guo Y; Kale N; Parisi JE; Pirko I; Mandrekar J; Bramow S; Metz I; Brück W; Lassmann H; Lucchinetti CF
    Ann Neurol; 2015 Nov; 78(5):710-21. PubMed ID: 26239536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
    Stuart WH
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological differences between classical phenothypes of multiple sclerosis.
    Iwanowski P; Losy J
    J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
    Tettey P; Siejka D; Simpson S; Taylor B; Blizzard L; Ponsonby AL; Dwyer T; van der Mei I
    Neuroepidemiology; 2016; 46(2):106-13. PubMed ID: 26784322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.